Janux Therapeutics, Inc. (JANX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$16.06-11.66%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · JANX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -27.5% |
| Our one-year growth estimate | diamond | -58.4% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 30.9 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name operates in a high-miss-rate industry and its industry peers have been missing lately. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
JANX — earnings miss
Dated 2026-08-06
Results of Operations and Financial Condition. On August 6, 2026, Janux Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three and six months ended June 30, 2026. A copy of the press release is attached hereto as Exhibit 99.1. The information in this Item and the exhibit attached hereto are being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or…
Why it matters: JANX013 is a planned partner to JANX007 in prostate cancer. Starting the trial would add another clinical program to that work.
Supportive ifJanux says the first patient entered the JANX013 clinical study by December 31, 2026.
Worry ifJanux makes no first-patient announcement by December 31, 2026. Or, it delays or stops the program.
Why it matters: Janux named a BMS collaboration candidate in Q1 and received a $35 million payment. More progress would show the partnership is moving ahead.
Supportive ifJanux or BMS announces a new named step or milestone for the partnered drug.
Worry ifJanux or BMS announces that the partnered program has stopped or that the license deal has ended.
Why it matters: New patient data can test JANX007 for antitumor activity as enrollment grows. It can also show how the darolutamide group is doing.
Watch forJanux presents more JANX007 data by June 30, 2027. The data show confirmed tumor responses and no new serious safety concern.
Also watch forThe data show no confirmed tumor responses or a new serious safety concern. Or, there is no update by June 30, 2027.
Why it matters: This is the first human data for Janux's autoimmune program. Safety and early activity can show whether the program can advance.
Watch forJanux reports its first Phase 1 data in H2 2026. There are no serious safety issues and signs of immune activity.
Also watch forJanux reports a serious safety issue or no sign of immune activity. Or, it delays the update beyond H2 2026.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$193 on $10,000 · ±1.9% | How much price usually moves either way. |
| Bad day | $450 loss on $10,000 · 4.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,494 loss on $10,000 · 64.9% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.